Touchlight, a biotechnology company pioneering enzymatic DNA production, has announced an extension of its fundraising round to a current aggregate total of $125 million. The round was led by Bridford Investments and Novator Partners.
The funding will be used for additional manufacturing capacity, R&D, and growth initiatives, and to expand the footprint of its Hampton-based facilities to enable production of up to one kilogram of GMP DNA a month once operational in the second quarter of next year.
The company also anticipates increasing its headcount from 65 in January to more than 125 by the end of this year. This expansion includes assembling dedicated commercial and marketing operations in the UK and North America.
Jonny Ohlson, chairman of Touchlight, said: “As the market for genetic medicines continues to expand at pace, we believe our dbDNA technology can be a key enabler of the industry, combining our revolutionary DNA manufacturing solution with a vector that sets a new regulatory gold standard. We are delighted that our investors also see the immense opportunities the field offer.”
Date published: September 16, 2021